Donor Lymphocyte Infusion–Mediated Graft-versus-Host Responses in a Preclinical Swine Model of Haploidentical Hematopoietic Cell Transplantation  Raimon.

Slides:



Advertisements
Similar presentations
Heather J. Symons, Moshe Y
Advertisements

Induction of Graft-versus-Leukemia (GVL) Effect without Graft-versus-Host Disease (GVHD) by Pretransplant Donor Treatment with Immunomodulators  Shoshana.
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
In Vitro Evaluation of Graft-versus-Graft Alloreactivity as a Tool to Identify the Predominant Cord Blood Unit before Double Cord Blood Transplantation 
Engraftment of quiescent progenitors and conversion to full chimerism after nonmyelosuppressive conditioning and hematopoietic cell transplantation in.
Adoptive Immunotherapy Against Allogeneic Kidney Grafts in Dogs with Stable Hematopoietic Trichimerism  Scott S. Graves, William J. Hogan, Christian Kuhr,
Complete allogeneic hematopoietic chimerism achieved by a combined strategy of in utero hematopoietic stem cell transplantation and postnatal donor lymphocyte.
Vaccination of Children following Allogeneic Stem Cell Transplantation
Patient HLA-DP–Specific CD4+ T Cells from HLA-DPB1–Mismatched Donor Lymphocyte Infusion Can Induce Graft-versus-Leukemia Reactivity in the Presence or.
Donor-Derived Natural Killer Cells Infused after Human Leukocyte Antigen– Haploidentical Hematopoietic Cell Transplantation: A Dose-Escalation Study  Inpyo.
Effect of Irradiation on Incidence of Post-Transplant Lymphoproliferative Disorder after Hematopoietic Cell Transplantation in Miniature Swine  Abraham.
Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease
Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8+ T-cell count on day +14 as a predictor.
Induction of Graft-versus-Leukemia (GVL) Effect without Graft-versus-Host Disease (GVHD) by Pretransplant Donor Treatment with Immunomodulators  Shoshana.
Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-
Treatment with a Rho Kinase Inhibitor Improves Survival from Graft-Versus-Host Disease in Mice after MHC-Haploidentical Hematopoietic Cell Transplantation 
Double Haploidentical Hematopoietic Stem Cell Transplantation Results in Successful Engraftment of Bone Marrow from Both Donors without Graft-versus-Host.
Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without.
Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft- versus-Host Disease after Hematopoietic Stem Cell Transplantation:
Twenty Years of Unrelated Donor Hematopoietic Cell Transplantation for Adult Recipients Facilitated by the National Marrow Donor Program  Chatchada Karanes,
A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide,
Significance of Ethnicity in the Risk of Acute Graft-versus-Host Disease and Leukemia Relapse after Unrelated Donor Hematopoietic Stem Cell Transplantation 
Survival and Function of MiHA Epitope-Specific Host CD8 TM Cells Following Ablative Conditioning and HCT  Alwi M. Shatry, Derry C. Roopenian, Robert B.
A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation 
Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease–Guided Multiple DLIs Could Improve Outcomes.
Impact of Pretransplantation Risk Factors on Post Transplantation Outcome of Patients with Acute Myeloid Leukemia in Remission after Haploidentical Hematopoietic.
Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions  Darius Sairafi, Mats Remberger, Michael.
Danielle M. Zerr, Michael Boeckh, Colleen Delaney, Paul J
Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source  Sharat Damodar,
Graft Transit Time Has No Effect on Outcome of Unrelated Donor Hematopoietic Cell Transplants Performed in Australia and New Zealand: A Study from the.
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302  Javier Bolaños-Meade, Juan Wu, Brent R. Logan,
Sequential Intensified Conditioning and Tapering of Prophylactic Immunosuppressants for Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell.
Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation  Jan Storek,
A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse  Zeyad Kanaan, MD, William Tse, MD, FACP 
Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.
B Cells and Transplantation: An Educational Resource
A comparison of gene transfer and antigen-loaded dendritic cells for the generation of CD4+ and CD8+ cytomegalovirus-specific T cells in HLA-A2+ and HLA-A2−
Post-Transplant Cyclophosphamide as Sole Graft-versus-Host Disease Prophylaxis Is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation.
Fludarabine and 2-Gy TBI is Superior to 2 Gy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial 
Eva Guinan, Leo Luzmik, Rupert Handgretinger, Ann Woolfrey 
Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells  Christian Scheffold, Yolanda C. Scheffold,
Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD4+25+ T cells to allow an effective graft-versus-leukemia response 
Haploidentical/Mismatched Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for T Cell Acute Lymphoblastic Leukemia  Yu Wang,
The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group  Amber B. Clemmons,
Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  Brent R. Logan, Mei-Jie Zhang,
Allogeneic Bone Marrow Transplantation in Models of Experimental Autoimmune Encephalomyelitis: Evidence for a Graft-versus-Autoimmunity Effect  Bart Van.
Pauline Damien, David S. Allan 
Raimon Duran-Struuck, George F. Murphy, Roderick T. Bronson, David H
What is quality in a transplant program?
Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.
Haplo-Cord Transplantation Using CD34+ Cells from a Third-Party Donor to Speed Engraftment in High-Risk Patients with Hematologic Disorders  Mi Kwon,
Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.
Raimon Duran-Struuck, Isao Tawara, Kathi Lowler, Shawn G
John E. Levine, Sophie Paczesny, Stefanie Sarantopoulos 
Potential Role of a Mismatched HLA-Specific CTL Clone Developed Pre-Transplant in Graft Rejection following Cord Blood Transplantation  Hiroto Narimatsu,
Blood and Marrow Transplant Handbook
Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.
Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.
Comparable Outcomes after HLA-Matched Sibling and Alternative Donor Hematopoietic Cell Transplantation for Children with Fanconi Anemia and Severe Aplastic.
Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:
Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter.
Frédéric Baron, Rainer Storb 
Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.
Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal.
What Role Is There for Antithymocyte Globulin in Allogeneic Nonmyeloablative Canine Hematopoietic Cell Transplantation?  Razvan Diaconescu, Marie-Térèse.
Graft-Derived Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation  Abir Bhattacharyya, Laïla-Aïcha.
Correlation of Infused CD3+CD8+ Cells with Single-Donor Dominance after Double-Unit Cord Blood Transplantation  Filippo Milano, Shelly Heimfeld, Ted Gooley,
Andrew R. Rezvani, Barry E. Storer, Katherine A. Guthrie, H
Presentation transcript:

Donor Lymphocyte Infusion–Mediated Graft-versus-Host Responses in a Preclinical Swine Model of Haploidentical Hematopoietic Cell Transplantation  Raimon Duran-Struuck, Abraham J. Matar, Rebecca L. Crepeau, Alexander G.S. Teague, Benjamin M. Horner, Vimukthi Pathiraja, Thomas R. Spitzer, Jay A. Fishman, Roderick T. Bronson, David H. Sachs, Christene A. Huang  Biology of Blood and Marrow Transplantation  Volume 22, Issue 11, Pages 1953-1960 (November 2016) DOI: 10.1016/j.bbmt.2016.08.011 Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Long-lasting donor unresponsiveness post-HCT. Three representative long-term tolerant animals that received a DLI after a RIC-HCT. Animal 13272 received 2 DLIs (arrows) on days 745 and 984 post-HCT, respectively. The first DLI was unmodified, whereas the second DLI was a “sensitized” DLI. Animal 14225 received a DLI on day 110 post-HCT. Animal 13476 received a DLI on day 482 post-HCT. Chimerism is shown in the top panels. Percent donor-derived chimerism is shown on the y axis and days post-transplantation on the x axis. CMLs were done at different time points. White squares represent anti-self responses, triangles anti–third party responses, and dark squares anti-donor responses. The y axis represents percent specific lysis (PSL) and the x axis represents the effector-to-target ratio (E:T). No effects after DLI were observed in these 3 representative animals (*P < .05). Biology of Blood and Marrow Transplantation 2016 22, 1953-1960DOI: (10.1016/j.bbmt.2016.08.011) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 DLI after leukapheresis. Animal 14980 received a DLI on day 218 post-HCT. The animal converted to donor chimerism without GVHD. Animal 19141 received a 37 million CD3+ T cell DLI on day 453 post-HCT, and subsequently developed GVHD. Animal 19560 underwent leukaphoresis on day 59 post-HCT and subsequently received a 50 million CD3 T cell DLI. Acute GVHD developed. Animals 17467 and 17469 each received a 50 million CD3 T cell DLI on days 96 and 62 after haplo-HCT, respectively. Animal 17467 had evidence of increased chimerism before succumbing to a non–GVHD-related condition. No effect was observed in animal 17469, and the DLI dose was escalated to 150 million (megadose) CD3+ T cell DLI on day 463 post-HCT. The animal converted to full donor chimerism and developed skin-only GVHD. Biology of Blood and Marrow Transplantation 2016 22, 1953-1960DOI: (10.1016/j.bbmt.2016.08.011) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Sensitized and CC DLIs. (A, left) Percent chimerism of animal 14376 after haploidentical HCT. A 50 million CD3+ T cell/kg DLI was delivered on day 36 and a “sensitized” DLI 1 year post-HCT (arrows). (A, middle) CML from a naive AC (used in comparison with the right panel). (A, right) CML from animal 14179 after being sensitized by host MHC-matched skin (to animal 14376, an AD). Assay was performed 92 days after skin grafting. (B, left) Percent chimerism of animal 16626 after haploidentical HCT. The animal was a low level chimera in all lineages. Animal 16626 received a donor AC DLI of 1 million CD3 T cells on day 152 post-HCT followed by a second DLI of 50 million AC donor-matched CD3+ T cells/kg (arrows). No effect of either DLI was observed. The third and last DLI was a CC DLI. This DLI was haplo-matched to donor cells (AC) but completely mismatched to the host MHC (AD). (B, middle) CML from chimeric animal 16626 responding to a third-party control while unresponsive to the PBMCs from the CC DLI donor. (B, right) CML using CC effectors and animal 16626 chimeric cells as targets before the DLI. Biology of Blood and Marrow Transplantation 2016 22, 1953-1960DOI: (10.1016/j.bbmt.2016.08.011) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions